Overview

A Study of Enzastaurin in Participants With Follicular Lymphoma

Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the antitumor activity, as measured by tumor response rate, of enzastaurin in participants with Follicular Lymphoma (FL).
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company